News
CDNA
20.61
+0.29%
0.06
Lobbying Update: CAREDX just disclosed $18,000 of lobbying spending
Barchart · 3d ago
Alger Small Cap Focus Fund Q3 2024 Commentary
Seeking Alpha · 3d ago
Alger Small Cap Growth Fund Q3 2024 Commentary
Seeking Alpha · 3d ago
CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Barchart · 3d ago
Molina Healthcare Expands Dual Eligible Services in Michigan, Idaho
NASDAQ · 4d ago
Ensign Group Rewards Shareholders With 4.2% Dividend Hike
Barchart · 5d ago
Weekly Report: what happened at CDNA last week (1209-1213)?
Weekly Report · 5d ago
Centene Unveils Its 2025 Guidance, Reaffirms 2024 Outlook
NASDAQ · 12/13 15:43
Community Health to Divest North Carolina Hospital for $280M
NASDAQ · 12/12 20:00
TC Biopharm announces partnership with CareDx
TipRanks · 12/11 12:10
TCBP PARTNERS WITH CAREDX TO SUPPORT ACHIEVE CLINICAL TRIAL USING ALLOCELL FOR PHARMACOKINETIC MONITORING OF ALLOGENEIC CELL THERAPY
Reuters · 12/11 12:00
Brookdale's 37-Month Growth Streak: Is BKD Stock a Safe Bet?
NASDAQ · 12/10 20:00
Weekly Report: what happened at CDNA last week (1202-1206)?
Weekly Report · 12/09 11:08
Insider Sale: Director at $CDNA (CDNA) Sells 5,000 Shares
Barchart · 12/04 06:08
Weekly Report: what happened at CDNA last week (1125-1129)?
Weekly Report · 12/02 11:08
Invesco Small Cap Equity Fund Q3 2024 Commentary
Seeking Alpha · 11/27 13:05
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Benzinga · 11/27 03:37
Invesco Health Care Fund Q3 2024 Commentary
Seeking Alpha · 11/26 17:37
Select Medical Distributes Concentra Shares to Shareholders
NASDAQ · 11/26 13:10
More
Webull provides a variety of real-time CDNA stock news. You can receive the latest news about Caredx through multiple platforms. This information may help you make smarter investment decisions.
About CDNA
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.